日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence

晚期卵巢癌PARP抑制剂维持治疗的真实世界结果：重点关注复发时的疾病模式和治疗方式

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.104119
Loverro, M; Marchetti, C; Salutari, V; Giannarelli, D; Vertechy, L; Capomacchia, F M; Caricato, C; Campitelli, M; Panico, C; Avesani, G; Cocciolillo, F; Rosati, A; Scambia, G; Fagotti, A
PARP
肿瘤
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

根据 BRCA1/2 突变类型和部位评估新诊断卵巢癌患者接受 PARP 抑制剂维持治疗的获益：一项多中心真实世界研究

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104533
Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D
肿瘤
肿瘤免疫
卵巢癌
BRCA1
PARP
发表日期：2025
文献求助 收藏

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response

关于“根据BRCA1/2突变类型和部位评估PARP抑制剂维持治疗对新诊断卵巢癌患者的益处：一项多中心真实世界研究”的来信回复：并非所有BRCA突变都相同：功能背景和突变类型是PARP抑制剂疗效的共同决定因素

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105299
Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D
肿瘤
肿瘤免疫
卵巢癌
BRCA1
PARP
发表日期：2025
文献求助 收藏

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

回复关于“根据BRCA1/2突变类型和部位评估PARP抑制剂维持治疗对新诊断卵巢癌患者的益处：一项多中心真实世界研究”的来信

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105289
Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D
肿瘤
肿瘤免疫
卵巢癌
BRCA1
PARP
发表日期：2025
文献求助 收藏

Validation of machine learning-based models to predict and explain the risk of ovarian cancer: a multicentric study on BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy

验证基于机器学习的模型预测和解释卵巢癌风险：一项针对接受风险降低性输卵管卵巢切除术的 BRCA 突变患者的多中心研究

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1574037
Loizzi, Vera; Comes, Maria Colomba; Arezzo, Francesca; Apostol, Adriana Ionelia; Bove, Samantha; Fanizzi, Annarita; Fruscio, Robert; Gregorc, Vanesa; Legge, Francesco; Mancari, Rosanna; Marchetti, Claudia; Negri, Serena; Russo, Giorgia; Vertechy, Laura; Scambia, Giovanni; Massafra, Raffaella; Cormio, Gennaro
肿瘤
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy

一项关于尼拉帕尼治疗老年原发性输卵管卵巢癌患者的真实世界观察性研究：重点关注安全性和有效性

期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-025-02914-y
Apostol, Adriana Ionelia; Bruno, Matteo; Sassu, Carolina Maria; Boccia, Serena Maria; Vertechy, Laura; Russo, Giorgia; Ruscito, Ilary; Capomacchia, Filippo Maria; Scambia, Giovanni; Fagotti, Anna; Marchetti, Claudia
肿瘤
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?

聚焦曲贝替定在卵巢癌中的应用：我们还需要了解什么？

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S451223
Boccia, Serena Maria; Sassu, Carolina Maria; Ergasti, Raffaella; Vertechy, Laura; Apostol, Adriana Ionelia; Palluzzi, Eleonora; Fagotti, Anna; Scambia, Giovanni; Marchetti, Claudia
肿瘤
肿瘤免疫
卵巢癌
发表日期：2024
文献求助 收藏

Socially interactive agents for robotic neurorehabilitation training: conceptualization and proof-of-concept study

用于机器人神经康复训练的社交互动代理：概念化和概念验证研究

期刊:Frontiers in Artificial Intelligence
影响因子:4.7
doi:10.3389/frai.2024.1441955
Arora, Rhythm; Prajod, Pooja; Nicora, Matteo Lavit; Panzeri, Daniele; Tauro, Giovanni; Vertechy, Rocco; Malosio, Matteo; André, Elisabeth; Gebhard, Patrick
发表日期：2024
文献求助 收藏

Gaze detection as a social cue to initiate natural human-robot collaboration in an assembly task

在装配任务中，目光检测作为一种社交线索，可以启动自然的人机协作。

期刊:Frontiers in Robotics and AI
影响因子:3
doi:10.3389/frobt.2024.1394379
Lavit Nicora, Matteo; Prajod, Pooja; Mondellini, Marta; Tauro, Giovanni; Vertechy, Rocco; André, Elisabeth; Malosio, Matteo
发表日期：2024
文献求助 收藏

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

MITO39：聚乙二醇化脂质体阿霉素（PLD）-曲贝替定治疗PARP抑制剂维持治疗后复发性卵巢癌的疗效和耐受性——一项意大利多中心卵巢癌观察性病例对照研究

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers16010041
Turinetto, Margherita; Ricotti, Andrea; Marchetti, Claudia; Pisano, Carmela; Zamagni, Claudio; Cassani, Chiara; Malaguti, Paola; Baldoni, Alessandra; Scollo, Paolo; Scandurra, Giuseppa; Parisi, Alessandro; Artioli, Grazia; Palaia, Innocenza; Vertechy, Laura; Bergamini, Alice; Picardo, Elisa; Tuninetti, Valentina; Scotto, Giulia; Scambia, Giovanni; Pignata, Sandro; Valabrega, Giorgio
PARP
肿瘤
肿瘤免疫
卵巢癌
发表日期：2023
文献求助 收藏